EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Drug-Induced Thrombotic Microangiopathy in Patients with Cancer

Wai Lun Will Pak iD, Nadia Al Haddad iD, Andrea Knezevic iD, Steven Salvatore iD, Surya Seshan iD, Ilya Glezerman iD, Edgar A Jaimes, Insara Jaffer Sathick iD

Kidney360 · 2026-09 · 7 (9) · 2046-2055

DOI: 10.34067/kid.0000001249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney360, online erschienen am 15.07.2026. Verfasst von Wai Lun Will Pak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Thrombotic Microangiopathies, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Gemcitabine, bevacizumab, and doxorubicin were the most common drugs implicated in drug-induced thrombotic microangiopathy in cancer. Cessation of the offending drug was the mainstay of management. The median overall survival was 2.1 years, and the median kidney failure‑free survival was 1.8 years after biopsy-confirmed diagnosis.

Background

Drug-induced thrombotic microangiopathy (TMA) is a major sequela of cancer therapies. The diagnosis of drug-induced TMA is often presumptive, making accurate clinical characterization difficult.

Methods

We retrospectively reviewed clinical presentation and outcomes of 53 patients with biopsy-proven renal TMA due to cancer therapies in a cancer center between 2001 and 2023.

Results

Median age at presentation was 64 (44–81) years, and our cohort was 72% (38/53) female. Most common malignancies treated were pancreatic (19%), breast (17%), ovarian (15%), and lung (15%) cancers. Forty-one patients (77%) presented with AKI, of which nine patients (17%) required dialysis. Most common implicated drugs were gemcitabine (51%); bevacizumab (25%); doxorubicin (15%); and various tyrosine kinase inhibitors (19%), including EGF receptor blocker erlotinib (4%). Cessation of the offending drug was the mainstay of management in 51 patients (96%); other treatment strategies included steroids (15%) and eculizumab (8%). After a median follow-up of 4 years (1.1–7.1), median overall survival was 2.1 years and median kidney failure‑free survival was 1.8 years. Among patients with AKI, 16 patients (39%) had kidney recovery within a year. One of nine patients requiring dialysis was weaned off within a year. Older age, lower GFR at presentation, and thrombocytopenia were associated with worse kidney prognosis. Chronic TMA was noted upon kidney biopsy in most of the patients (85%). Pathologic findings associated with worse kidney outcome were the presence of microvascular thrombi and endothelial swelling.

Conclusions

Although limited by its retrospective nature, our study suggests that doxorubicin and erlotinib are underrecognized causes of drug-induced TMA. Many patients' biopsies had chronic changes in glomeruli, arterioles, and small arteries, indicating that mild, ongoing endothelial injury is present before the development of overt TMA. Clinical vigilance with early cessation of the offending drug may help kidney recovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombotic MicroangiopathiesNeoplasmsAntineoplastic AgentsHumansFemaleRetrospective StudiesDeoxycytidineMiddle AgedGemcitabineMaleBevacizumabAgedAged, 80 and overAdultDoxorubicin

Stichwörter der Autor:innen

onconephrology

Substanzen

DeoxycytidineGemcitabineBevacizumabAntineoplastic AgentsDoxorubicin

Autor:innen und Institutionen

  • Renal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • United Christian Hospital, Hong Kong SAR, China.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • Weill Cornell Medical College, New York, New York.

ORCID-Profile: Wai Lun Will Pak, Nadia Al Haddad, Andrea Knezevic, Steven Salvatore, Surya Seshan, Ilya Glezerman, Insara Jaffer Sathick

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Pak, W. L. W., Al Haddad, N., Knezevic, A., Salvatore, S., Seshan, S., Glezerman, I., Jaimes, E. A., & Jaffer Sathick, I. (2026). Drug-Induced Thrombotic Microangiopathy in Patients with Cancer. Kidney360, 7(9), 2046-2055. https://doi.org/10.34067/kid.0000001249

Vancouver

Pak WLW, Al Haddad N, Knezevic A, Salvatore S, Seshan S, Glezerman I, et al. Drug-Induced Thrombotic Microangiopathy in Patients with Cancer. Kidney360. 2026;7(9):2046-2055. doi:10.34067/kid.0000001249

BibTeX
@article{Pak2026,
  author = {Pak, Wai Lun Will and Al Haddad, Nadia and Knezevic, Andrea and Salvatore, Steven and Seshan, Surya and Glezerman, Ilya and Jaimes, Edgar A and Jaffer Sathick, Insara},
  title = {Drug-Induced Thrombotic Microangiopathy in Patients with Cancer},
  journal = {Kidney360},
  year = {2026},
  volume = {7},
  number = {9},
  pages = {2046--2055},
  doi = {10.34067/kid.0000001249}
}
Kostenlos starten →